热门资讯> 正文

Solid Biosciences将开始在美国和加拿大测试SGT-501

2025-07-09 21:36

Solid Biosciences (NASDAQ:SLDB) said that the U.S. FDA and Health Canada has approved its gene therapy, SGT-501,for the treatment of heart disease caused by genetic disorder.
The company expects to initiate a first-stage trial to evaluate SGT-501 as a treatment of the disorder, called catecholaminergic polymorphic ventricular tachycardia, in the fourth quarter of 2025.

More on Solid Biosciences

Seeking Alpha’s Quant Rating on Solid Biosciences
Historical earnings data for Solid Biosciences
Financial information for Solid Biosciences

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。